4 reports

  • Pipeline analysis
  • Vendor landscape

Out of this, ##, ## are affected by heart attack for the first time and ##, ## people have already had a heart attack.

  • Cardiovascular Disease
  • Heart Attack
  • AstraZeneca PLC
  • CicloMulsion AG
  • NSTEMI group

The ideal AMI marker is one that has high clinical sensitivity and specificity, appears soon after the onset of a heart attack; remains elevated for several days following a heart attack and can be assayed with a rapid turnaround time.

  • Heart Attack
  • Point Of Care Testing
  • Abbott Laboratories, Inc.
  • Alere Inc.
  • Beckman Coulter, Inc.
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Cardiovascular Disease
  • Heart Attack
  • World
  • Product Initiative
  • Aurobindo Pharma Limited
  • JUN 01, 2015: NEUROVIVE REPORTS TOPLINE RESULTS OF PHASE III CIRCUS STUDY IN ACUTE MYOCARDIAL INFARCTION
  • MAY 25, 2015: NEUROVIVE PHARMACEUTICAL: TOPLINE RESULT OF PHASE III STUDY OF CICLOMULSION IN ACUTE MYOCARDIAL INFARCTION EXPECTED THIS QUARTER

RESEARCH INTO CICLOMULSION S EFFICACY BEYOND THE TREATMENT OF REPERFUSION INJURY FOLLOWING HEART ATTACK GREW OUT OF THE CONCEPT OF MITOCHONDRIAL PROTECTION IN CONNECTION WITH ORGAN INJURY FOCUSING ON HEART DISEASE.

  • Heart Attack
  • Therapy
  • World
  • Product Initiative
  • CicloMulsion AG